Date: 2014-05-19
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: veliparib (ABT-888)
Action
mechanism: poly ADP ribose polymerase PARP inhibitor/PARP inhibitor. Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. Discovered by AbbVie researchers, veliparib is being developed to help prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation.
Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 3 studies in non-small cell lung cancer and breast cancer.
Disease: metastatic breast cancer
Therapeutic area: Cancer - Oncology
Country: Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Republic of Korea, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, UK, USA
Trial
details: The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer. (NCT02163694)
Latest
news: * On May 19, 2014, a new Phase 3 trial with veliparib, an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor was published on ClinicalTrials.gov "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer".
